Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis
Dr. Miller has research funding from Bracco, Inc for FDG/Rb-82 PET perfusion imaging in CS, unrelated to the current study, as well as consulting for Bracco, Pfizer, GE, and Alnylam. The remaining authors have no funding to report. Dr. Rosenfeld has received Fellowship Support from: Abbott, Boston Scientific and Medtronic. The remaining authors have declared that no competing interests exist.
- 3.Ohira H, Birnie DH, Pena E, et al. Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2016;43:259-69.CrossRefGoogle Scholar